Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cytheris, a biopharmaceutical company, has announced to present the data from an interim analysis of its Eclipse II Hepatitis C Phase I/IIa multicenter study at the 62nd annual meeting of the American Association for the Study of Liver Diseases (AASLD).
Subscribe to our email newsletter
The meeting will be held in San Francisco, US between 4 and 8 November 2011.
The study intended to assess the efficacy of immune-modulator, recombinant human Interleukin-7 (CYT107).
Recombinant human interleukin-7 (CYT107) is a critical immune-modulator for immune T-cell recovery and enhancement.
CYT107 is added to peginterferon and ribavirin (SOC), for four weeks, in genotype one and four treatment experienced patients defined as nonresponders to SOC.
The treatment has induced a broad immune response associated with HCV viral clearance in genotype one and four patients nonresponders to Peg-IFN and RBV.